Artelo Biosciences (NASDAQ:ARTL) Issues Earnings Results, Misses Estimates By $3.22 EPS

Artelo Biosciences (NASDAQ:ARTL) issued its quarterly earnings data on Thursday. The company reported ($4.00) EPS for the quarter, missing the consensus estimate of ($0.78) by ($3.22), FiscalAI reports.

Artelo Biosciences Trading Up 1.3%

ARTL traded up $0.03 on Thursday, reaching $2.34. The stock had a trading volume of 84,081 shares, compared to its average volume of 2,318,749. Artelo Biosciences has a fifty-two week low of $2.30 and a fifty-two week high of $85.80. The firm has a 50-day moving average of $4.94 and a 200-day moving average of $5.10. The company has a market capitalization of $2.19 million, a price-to-earnings ratio of -0.04 and a beta of 0.05.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ARTL. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a research note on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.